China Shineway Pharmaceutical Group Limited (FRA:C1S)

FRA:C1S Statistics

Total Valuation

FRA:C1S has a market cap or net worth of EUR 705.95 million. The enterprise value is -98.21 million.

Market Cap	705.95M
Enterprise Value	-98.21M

Important Dates

The next estimated earnings date is Thursday, November 27, 2025.

Earnings Date	Nov 27, 2025
Ex-Dividend Date	Sep 9, 2025

Share Statistics

Current Share Class	755.40M
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	72.59%
Owned by Institutions (%)	6.52%
Float	207.04M

Valuation Ratios

The trailing PE ratio is 7.17 and the forward PE ratio is 7.03.

PE Ratio	7.17
Forward PE	7.03
PS Ratio	1.78
PB Ratio	0.76
P/TBV Ratio	0.78
P/FCF Ratio	7.43
P/OCF Ratio	6.15
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.00
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.03

Financial Position

The company has a current ratio of 3.69, with a Debt / Equity ratio of 0.04.

Current Ratio	3.69
Quick Ratio	3.36
Debt / Equity	0.04
Debt / EBITDA	0.48
Debt / FCF	0.43
Interest Coverage	70.69

Financial Efficiency

Return on equity (ROE) is 10.94% and return on invested capital (ROIC) is 5.10%.

Return on Equity (ROE)	10.94%
Return on Assets (ROA)	3.98%
Return on Invested Capital (ROIC)	5.10%
Return on Capital Employed (ROCE)	8.12%
Revenue Per Employee	138,639
Profits Per Employee	34,337
Employee Count	3,220
Asset Turnover	0.33
Inventory Turnover	1.15

Taxes

In the past 12 months, FRA:C1S has paid 27.35 million in taxes.

Income Tax	27.35M
Effective Tax Rate	21.74%

Stock Price Statistics

The stock price has decreased by -16.67% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-16.67%
50-Day Moving Average	0.91
200-Day Moving Average	0.91
Relative Strength Index (RSI)	52.08
Average Volume (20 Days)	1,300

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:C1S had revenue of EUR 397.48 million and earned 98.45 million in profits. Earnings per share was 0.13.

Revenue	397.48M
Gross Profit	291.59M
Operating Income	76.81M
Pretax Income	125.79M
Net Income	98.45M
EBITDA	82.60M
EBIT	76.81M
Earnings Per Share (EPS)	0.13

Balance Sheet

The company has 827.42 million in cash and 40.57 million in debt, giving a net cash position of 786.85 million.

Cash & Cash Equivalents	827.42M
Total Debt	40.57M
Net Cash	786.85M
Net Cash Per Share	n/a
Equity (Book Value)	928.26M
Book Value Per Share	1.23
Working Capital	775.55M

Cash Flow

In the last 12 months, operating cash flow was 114.74 million and capital expenditures -19.76 million, giving a free cash flow of 94.98 million.

Operating Cash Flow	114.74M
Capital Expenditures	-19.76M
Free Cash Flow	94.98M
FCF Per Share	n/a

Margins

Gross margin is 73.36%, with operating and profit margins of 19.32% and 24.77%.

Gross Margin	73.36%
Operating Margin	19.32%
Pretax Margin	31.65%
Profit Margin	24.77%
EBITDA Margin	20.78%
EBIT Margin	19.32%
FCF Margin	23.90%

Dividends & Yields

This stock pays an annual dividend of 0.06, which amounts to a dividend yield of 6.26%.

Dividend Per Share	0.06
Dividend Yield	6.26%
Dividend Growth (YoY)	-18.05%
Years of Dividend Growth	2
Payout Ratio	42.87%
Buyback Yield	n/a
Shareholder Yield	6.26%
Earnings Yield	13.95%
FCF Yield	13.45%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:C1S has an Altman Z-Score of 3.7 and a Piotroski F-Score of 5.

Altman Z-Score	3.7
Piotroski F-Score	5